Sapience Therapeutics Lucicebtide Phase 2 GBM Specific Data Point: 28.4-Month Projected Median PFS Versus 4.0-6.9 Month Historic Benchmark in Newly Diagnosed Glioblastoma
Sapience Therapeutics' May 21 ASCO 2026 data update on lucicebtide (ST101) — a first-in-class C/EBPβ peptide antagonist — included a specific data point worth surfacing for the Tuesday cycle. In the Phase 2 Window-of-Opportunity study (n=9 evaluable as of April 27 data cutoff), patients with newly diagnosed glioblastoma (ndGBM) treated with lucicebtide plus standard-of-care chemoradiation achieved a projected median progression-free survival of 28.4 months — meaningfully exceeding the 4.0-6.9 month historic benchmark range. Six of nine patients remain alive past 22.3 months against a historical median OS range of 14.6-17.0 months. Median overall survival has not yet been reached. Lucicebtide crossed the blood-brain barrier with confirmed tumor uptake and target engagement via negative enrichment of the C/EBPβ regulon in tumor and myeloid cells. The poster session is scheduled for Monday June 1.